KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Investments: 2012-2024

Historic Long-Term Investments for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Mar 2024 value amounting to $11.7 million.

  • Supernus Pharmaceuticals' Long-Term Investments fell 78.47% to $11.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.7 million, marking a year-over-year decrease of 78.47%. This contributed to the annual value of $16.6 million for FY2023, which is 82.30% down from last year.
  • As of Q1 2024, Supernus Pharmaceuticals' Long-Term Investments stood at $11.7 million, which was down 29.82% from $16.6 million recorded in Q4 2023.
  • In the past 5 years, Supernus Pharmaceuticals' Long-Term Investments registered a high of $534.7 million during Q1 2020, and its lowest value of $11.7 million during Q1 2024.
  • Its 3-year average for Long-Term Investments is $71.5 million, with a median of $54.2 million in 2023.
  • Its Long-Term Investments has fluctuated over the past 5 years, first climbed by 24.20% in 2021, then tumbled by 82.30% in 2023.
  • Supernus Pharmaceuticals' Long-Term Investments (Quarterly) stood at $350.4 million in 2020, then plummeted by 65.99% to $119.2 million in 2021, then decreased by 21.21% to $93.9 million in 2022, then slumped by 82.30% to $16.6 million in 2023, then crashed by 78.47% to $11.7 million in 2024.
  • Its last three reported values are $11.7 million in Q1 2024, $16.6 million for Q4 2023, and $25.1 million during Q3 2023.